Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of
chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery)
or adjuvant (after surgery) treatment of previously untreated adults with gastric and
gastroesophageal junction (GEJ) adenocarcinoma.